Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.
about
Soluble RAGE: a hot new biomarker for the hot joint?Soluble Receptor for Advanced Glycation End Product: A Biomarker for Acute Coronary SyndromeLow levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or realityThe multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic diseaseIntraoperative sRAGE kinetics. A new age-related outcome predictor of cardiac surgery.The Association of Serum Thrombomodulin with Endothelial Injuring Factors in Abdominal Aortic Aneurysm.Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients.Elevation of high-mobility group box 1 after clinical autologous islet transplantation and its inverse correlation with outcomesPercutaneous treatment of peripheral vascular disease: the role of diabetes and inflammationEffect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patientsMeta-analysis of RAGE gene polymorphism and coronary heart disease riskSoluble receptor for advanced glycation end products in critically ill patients and its associations with other clinical markers and 28-day mortality.-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease.Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE)Plasma levels of sRAGE, loss of aeration and weaning failure in ICU patients: a prospective observational multicenter studySoluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study.Association of four genetic polymorphisms of AGER and its circulating forms with coronary artery disease: a meta-analysis.Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS)Fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome.Plasma levels of soluble receptor for advanced glycation end products in patients with acute respiratory distress syndromeAn interactive association of advanced glycation end-product receptor gene four common polymorphisms with coronary artery disease in northeastern Han Chinese.Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancersRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study.The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes.Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan StudyPulmonary biomarkers based on alterations in protein expression after exposure to arsenic.Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis.Soluble RAGEs - Prospects for treating & tracking metabolic and inflammatory diseaseRelationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal WomenEmerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway.Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.A soluble receptor for advanced glycation end-products inhibits hypoxia/reoxygenation-induced apoptosis in rat cardiomyocytes via the mitochondrial pathway.Lung inflammation biomarkers and lung function in children chronically exposed to arsenicReduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome.Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.Circulating soluble receptor for advanced glycation end products is decreased and inversely associated with acute phase response in chronic spontaneous urticaria.sRAGE and risk of diabetes, cardiovascular disease, and deathSerum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
P2860
Q24817185-F631D677-1E6B-4CC7-8604-510A1F4FD806Q26780488-24118E65-7E85-43C8-A7EA-7139EC3811A6Q26859793-BF1AFED3-3A96-4589-A150-F41D5A1B10F0Q28830568-F4E06865-A6E3-4540-8D2A-900D4286B8B8Q30317651-EDAB7C54-A4B6-48C1-87E2-E493C83D99F3Q33572127-B5B09F90-619E-41DD-BB11-897FB517B633Q33739280-79BB9675-59AB-47CB-B4C0-1A859B6CFF4DQ33894332-6A142905-D3A7-417A-834A-E304CC9F0120Q34018425-323C560A-59FA-4DB8-8241-1A29BC4D4C44Q34362687-F96C9102-1C8A-4E0E-9514-C8774E206601Q34510507-DC0960E0-D462-4C93-ABA8-9C0E10515B81Q34564061-756EB9B1-F101-4645-80C0-71D13F9F84C1Q34672674-8999BF2A-F8AE-4827-BD49-983F827E8B5AQ34679433-8A8EECC7-AC3C-4E7B-A0AE-890877AF8EC7Q34749439-303416C3-5CAD-4CDF-9738-D687BC2FC3D2Q34774357-001CBC87-A146-4AD6-9354-AB09E54F8766Q34876873-AC5EF64B-7D1C-4F0B-BC29-17FAD045113EQ34949171-4AFDD096-BD3F-4531-AF33-6A6BA15437D7Q34994616-7A9C9D48-CE33-424F-8674-D64978CB575FQ35017280-9751B16E-DE64-44EF-A206-2F681C7E6980Q35025330-23B609E2-AC45-4BBF-919F-CE6793D0F33EQ35093747-820671E4-32E6-4AF1-9722-5149D3410185Q35097016-D393C7CA-C2CB-4B71-ACA2-49E9789F4FF1Q35160764-71731BFB-7AF1-49A3-AFA1-BFC1BA4E7DB9Q35234754-C19F8972-C8BA-4D9A-91EB-B7F0AA93276FQ35752436-580F9483-E2CF-4BA4-A605-22B33833DFAFQ35837912-46FB39B2-7E14-4159-AEFB-A6EE0F2FA300Q35944988-62F07AF3-30C8-457D-BF89-47B19FD74D00Q35991574-0156817C-4094-40E4-A7B6-8B9C2DDE46DEQ36047141-24D21652-9725-4809-9B71-56959DBDD810Q36207823-7211440C-6924-4208-9C1D-A9B6E12AC814Q36263332-06AA95BA-0861-4534-9D5F-8EF7FF7BAD25Q36321887-072067EE-B7AA-4D3E-98FB-222E063E6ACFQ36575194-12E8FE51-FD3C-4855-AB15-2B0C0A1C693BQ36605862-72498D0D-BE99-4FE2-A5AD-B83D901D0FDFQ36735682-E2AD4D38-92E0-41E5-8DD8-068B7D0794E3Q36772782-B25CA1C2-1118-4F8F-B873-92EB7B2235FDQ36867450-2F0BD1C3-CA68-4140-A0B1-2DBCFE25D07BQ36935766-3E77BF45-C26C-45A9-9B89-892DDA43A0D1Q36969021-8C28C1B2-95ED-494F-97DF-D58E74E12562
P2860
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@ast
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@en
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@nl
type
label
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@ast
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@en
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@nl
prefLabel
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@ast
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@en
Plasma levels of soluble recep ...... ry disease in nondiabetic men.
@nl
P2093
P1476
Plasma levels of soluble recep ...... ery disease in nondiabetic men
@en
P2093
Chiara Belvito
Colomba Falcone
Diego Geroldi
Maria P Buzzi
Mariaclara Cuccia
P304
P356
10.1161/01.ATV.0000160342.20342.00
P407
P577
2005-02-24T00:00:00Z